has received FDA approval of Levetiracetam Extended-Release tablets, a generic equivalent of Keppra XRÂ®.
Shipping in the United States commenced immediately following approval.
According to IMS Health, Keppra XRÂ® had US total sales of approximately USD161 million for the 12 months ending 30 June 2011.
EnquiriesDavid Myers, Jr.Senior Manager, Products & CommunicationsTel: +1 (973) 993 4503E-mail: email@example.com Keppra XR Â® is a trademark owned by a party other than Actavis.
has begun shipping Oxymorphone Hydrochloride Extended-Release Tablets, CII
7.5mg and 15mg, a generic equivalent of Opana ERÂ® in the United States.
Approximately one third of Actavis Group hfâ€™s sales are generated in North America, Actavis'
single largest market.
Based in Morristown, NJ, Actavis Inc.
has U.S. manufacturing facilities in Elizabeth, NJ and Lincolnton, NC.
also has research and development facilities in Elizabeth, NJ, Owings Mills, MD and Sunrise, FL. Actavis Group hf is one of the worldâ€™s leading generic pharmaceutical companies specializing in the development, manufacture and sale of generic pharmaceuticals.
The company has operations in 40 countries, with more than 10,500 employees.
Opana ER Â® is a trademark owned by a party other than Actavis
Information in this press release may contain forward-looking statements with respect to the financial condition, results of operations and businesses of Actavis
The newly launched products include Fosinopril HCT (cardiovascular) and Lisinopril HCT (cardiovascular), both of which were first to market in Bulgaria; Irinotecan (oncology), which Actavis
has also recently marketed in the United States; Sertraline (antidepressant) and Bicalutamide (oncology).
today announced the launch of the antiepileptic drug Topiramate in the UK, Germany, France and Switzerland.
The product was launched on day one as the originatorâ€™s patent expired on 25 September.
was first to market in all four countries.
Topiramate is used to treat epilepsy and will be sold in tablets of 25mg, 50mg, 100mg and 200mg.
Topiramate is the generic equivalent of Janssen-Cilaqâ€™s TopamaxÂ® / EpitomaxÂ®.
ccording to IMS Health, Janssen-Cilagâ€™s product had sales of approximately â‚¬98 mln for the 12 months ended June 2009 in the four countries of UK, Germany, France and Switzerland.
was developed by Actavisâ€™ R&D in Iceland and in produced by Actavis
in Hafnarfjordur, Iceland.
has already launched Topiramate
in other countries where no patent protection was in place, including Portugal in 2007.
Tue, 29 Sep 2009 06:00:00 GMT
Actavis launches Finasteride as patent expires in France
launched Finasteride in France on day one, when the originatorâ€™s patent expired on Monday
The distribution of the product has already commenced.
Finasteride Actavis was launched by the company under its brand name, and at the same time by various Medis clients.
, Actavisâ€˜ Third Party sales division, handles the sales of intellectual property and pharmaceutical products to other pharmaceutical companies in most EU nations and elsewhere and has marketing authorisations in over 50 countries.
Finasteride, used for the treatment of prostate cancer, is the generic equivalent of Merckâ€˜s ProscarÂ®.
Finasteride Actavis is available in tablets of 5mg in France.
was developed by Actavis
in Iceland and has already been launched by Actavis and its third party clients in many other European countries and in the United States.
has well over 300 product and market launches on the Groupâ€™s various markets to date in 2009.
was awarded the â€œInnovations in Genericsâ€ award at this yearâ€™s Pharmacy Business Awards in the United Kingdom, winning the award for the second year in a row.Actavis
, the second largest supplier of generic medicine in the UK, has launched up to 165 new products in the past three years; 60 of which were launched in 2009 alone.
Actavisâ€™ commitment to day one patent expiries has resulted in numerous day one launches including Lercanidipine and Losartan, with further major patent expiry launches in the pipeline this year.Other outstanding achievements by Actavis in the UK include the introduction of vialshieldÂ® hospital packaging, which provides unique safety and protection for vials against breakages and spills.
Actavis also focused on providing robust clarity for product labelling and layout with the redesign of Actavisâ€™ hospital packaging and the subsequent launch of â€œSafety Packagingâ€.
Jonathan Wilson, Director at Actavis UK: â€œWinning the award demonstrates how Actavis is on the cutting edge of innovation when it comes to patient safety and also the ease of use for our products.
has launched Valaciclovir in Switzerland on day one after the patent expired on 27 June.
Valaciclovir is used to treat herpes virus infections.
Valaciclovir Actavis has already been launched in a number of markets Ã Europe, including France and the UK, and will soon be entering other European markets.
In Switzerland, it was launched under the Actavis brand as well as by customers of Medis
- Actavisâ€™ Third-party sales division.
Valaciclovir is marketed by GlaxoSmithKline
under the brand names ValtrexÂ® / ZelitrexÂ®.
The equivalent generic drug from Actavis
is available in Switzerland in 500mg tablets.
Valaciclovir (also spelt valacyclovir) is used to treat herpes virus infections, including cold sores, shingles and genital herpes in adults as well as chickenpox and cold sores in children.
was developed by Actavis R&D and is manufactured by Actavis in Iceland.
Quinapril will be sold by the division's customers, who will then sell the product under their own brand.Quinapril, is primarily used for the treatment of hypertension in patients with cardiovascular problems, and is manufactured by Actavis
Germany is an important market for Actavis
and we are confident of making further progress in this region.â€
Mr Wessman visited the Zagreb Stock Exchange to discuss the possibility of listing Actavis
in Croatia on completion of the acquisition.
PLIVA and Actavis
compliment each other in almost every respect.
They have complimentary geographic coverage, therapeutic focus and a product pipeline with minimal overlap.
This will make the integration process very straight forward and the benefits of the combination immediate.
will be a crucial part of the enlarged Group and its ongoing strategy.
We want to encourage the ongoing support of local investors, which is why I
have met with the Zagreb Stock Exchange today to ensure that a listing in Croatia is something that Actavis
can achieve quickly.
has entered into a multi-year exclusive agreement with Pfizer
for the supply of oncology products.
has received approval from the US Food & Drug Administration to market Epirubicin Hydrochloride Injection.
Epirubicin Hydrochloride Injection, the generic to Pfizerâ€™s EllenceÂ®, has been approved in 10 mg / 5 mL, 50 mg / 25 mL, and 200 mg / 100 mL configurations and is indicated as a component of adjuvant therapy in patients with evidence of axillary node tumour involvement following resection of primary breast cancer.
Annual US sales of brand and generic Epirubicin HCl Injection were US$17.5 million for the 12 months ending June 2008 according to IMS Health data.
Actavis currently markets over 50 hospital products worldwide, with a focus on oncology products and a growing range of anti-infectives, local anesthetics and analgesics.
Epirubicin HCl Injection, is developed by Actavis scientists in Romania.
second injectable oncology product in the United States; Actavis
received FDA approval for Irinotecan Hydrochloride Injection
Mon, 06 Oct 2008 05:00:00 GMT
Pilocarpine Actavis tablets US
Actavis has begun shipping Pilocarpine Hydrochloride 7.5mg tablets in the U.S., to complement Pilocarpine 5mg tablets that the company currently offers in the U.S. Pilocarpine Tablets are used to treat dryness of the mouth and throat caused by a decrease in the amount of saliva that may occur after radiation treatment for cancer of the head and neck or in patients with Sjogren's syndrome.
has acquired a 90% share in Zhejiang Chiral Medicine Chemicals Company
for an undisclosed amount.
is specialized in research, development and production of active pharmaceutical ingredients (APIs).
The acquisition is part of Actavisâ€™ strategy to get direct access to low cost API manufacturing.
has already established an API R&D centre in India
with a pipeline of 70 products.
In addition to building up a strategic position in APIs, Actavis
produces generic pharmaceuticals at 21 production sites in 13 countries, with an annual capacity of 24 bn tablets and capsules.
In China, Actavis
operates a manufacturing site in Guangdong, which produces tablets, capsules, suspensions, solutions, creams and ointments.